This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.
Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.
The most recent National Healthcare Safety Network annual survey shows that 78% of US hospitals now have sepsis committees, an increase from 73% in 2022.
The platform, PfizerForAll, looks to enable telemedicine for certain health conditions and information about vaccination access.
The FDA, CDC, and state health departments have been monitoring foodborne illnesses this August including Listeria, Salmonella, and Clostridium botulinum.
A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.
As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.
In this episode, clinicians discuss challenges associated with these topics and offer management insights on them.
As with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.
MP Biomedicals’ tests detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.
Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.
The town of Plymouth decided to prohibit people from using the parks from dusk to dawn due to concerns over eastern equine encephalitis after a man contracted the rare disease in the state.
The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.
Two recent CDC Morbidity and Mortality Weekly Report (MMWR) studies show stable overall vaccination rates for 2023 but a decline in HPV vaccination rates for certain birth cohorts.
In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.
Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy indicated for a healthcare-associated infection, while also seeking new opportunities for the product worldwide.
In this case study, clinicians review a challenging case.
This virus is known for causing mild illness and the distinctive "slapped cheek" rash in children and has recently shown an unusual increase in activity.
Clinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.
This week, Pfizer-BioNTech's Phase 3 trial of a COVID-19 and influenza combination vaccine yielded mixed results, mpox as a global health emergency emphasizes need for coordinated international response, ongoing challenges with MRSA infections, and more
Understanding the potential and limitations of new Acinetobacter baumannii active therapies.
The study found that vancomycin is more effective than metronidazole in achieving event-free survival for C difficile infections across all infection severity levels.
Transmission to humans is limited in the US, but concerns linger, especially in the wake of the COVID-19 pandemic.
The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.
In our latest roundtable series, we cover different aspects of HIV care. In this series, clinicians discuss diagnosis, therapies such as long-acting injectables, treating patients with multidrug resistance and more.
A focus group study reviewed provider practices to learn more about patient management and explore the potential to follow up with clinicians on important takeaways.
The NIH’s RECOVER Initiative has developed new symptom indices for Long COVID in school-age children and adolescents to find 14 symptoms overlapping between the two groups.
This study provides evidence that using DAAs reduces liver fibrosis and improves clinical outcomes.
In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.
The results indicate that paternal hepatitis B virus infection before pregnancy is linked to a 40% higher risk of congenital heart diseases in their children.
